PHASE III, RANDOMIZED, ACTIVE-COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA.

Phase 3 Completed 50 enrolled Laboratorios Richmond S.A.C.I.F. Laboratorios Richmond Colombia SAS · collab

RandomizedCrossoverTriple-blindTreatment

Summary

To evaluate the efficacy of Nifedipine 30mg Extended-Release Richmond versus Nifedipine 30mg extended-release with a current registration in Colombia, measured by the proportion of patients with controlled blood pressure in adult patients diagnosed with mild or moderate hypertension at week 8 of follow-up.

Timeline

Start: 2024-07-09
Primary completion: 2025-04-15
Completion: 2025-08-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nifedipine	Other / unclassified	30 mg	—

PHASE III, RANDOMIZED, ACTIVE-COMPARATOR CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF NIFEDIPINE 30MG EXTENDED-RELEASE IN ADULT PATIENTS DIAGNOSED WITH MILD OR MODERATE HYPERTENSION IN COLOMBIA.

Summary

Timeline

Drugs

Indications